ADMA — ADMA Biologics, Inc.
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 685
- Website: https://www.admabiologics.com
Latest SEC filings for ADMA
- SCHEDULE 13G — 2026-08-07
- 10-Q — 2026-08-05
- 8-K — 2026-08-05
- 8-K — 2026-06-02
- 8-K — 2026-05-06
- 10-Q — 2026-05-06
- 8-K — 2026-05-04
- ARS — 2026-04-15
- 8-K — 2026-03-27
- SCHEDULE 13G/A — 2026-03-26
Latest ADMA news
- — Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing (Zacks Investment Research)
- — Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy? (zacks.com)
- — Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? (Zacks Investment Research)
- — Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors (Zacks Investment Research)
- — Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors (zacks.com)
- — ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know (Zacks Investment Research)
- — ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know (zacks.com)
- — Here's Why Adma Biologics (ADMA) Fell More Than Broader Market (zacks.com)
Educational tool only — not investment advice.